Abstract: Sorafenib (BAY 43-9006) is a pioneering multi-kinase inhibitor that has served as a cornerstone first-line systemic therapy for advanced hepatocellular carcinoma (HCC). While it effectively suppresses tumor proliferation and angiogenesis, its long-term clinical efficacy is severely hindered by the rapid emergence of primary and acquired drug resistance. This comprehensive review synthesizes recent findings on the multifaceted mechanisms driving sorafenib resistance in HCC, including epigenetic modifications, non-coding RNA regulation, metabolic reprogramming, altered transport processes, and tumor microenvironment (TME) dynamics. Furthermore, it explores the role of regulated cell death pathways, such as ferroptosis and autophagy, and the expansion of cancer stem cells (CSCs). To overcome these limitations, emerging therapeutic strategies are discussed, highlighting the potential of combination therapies, smart nanomedicine delivery systems, and precision medicine approaches utilizing patient-derived models and circulating tumor DNA (ctDNA).
1. Introduction
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality globally, often arising in patients with chronic liver inflammation due to viral infections, alcohol abuse, or metabolic syndromes [1]. Because more than 50% of HCC patients are diagnosed at an advanced stage, systemic therapy is frequently required [1]. Sorafenib (BAY 43-9006) was the first targeted agent to demonstrate a survival benefit in advanced HCC, establishing it as a standard first-line treatment [1][8]. Despite its initial success, only approximately 30% of patients benefit from sorafenib, and among those who do, acquired resistance typically develops within six months [1]. The high rate of drug resistance, coupled with tumor heterogeneity, remains the primary obstacle to improving patient survival [7]. Consequently, elucidating the molecular mechanisms underlying sorafenib resistance and developing novel strategies to counteract it have become critical research priorities in HCC management.
2. Pharmacological Activity
Sorafenib is an oral multi-kinase inhibitor that exerts broad-spectrum antitumor activity by simultaneously targeting multiple intracellular and cell-surface kinases. Its primary pharmacological mechanism involves the dual inhibition of tumor cell proliferation and tumor angiogenesis [1][3]. Sorafenib blocks the Raf/MEK/ERK signaling pathway by inhibiting Raf-1 and B-Raf, which directly suppresses tumor cell division [1][8]. Concurrently, it targets receptor tyrosine kinases (RTKs) involved in angiogenesis, including vascular endothelial growth factor receptors (VEGFR-2 and VEGFR-3), platelet-derived growth factor receptor beta (PDGFR-β), and c-KIT [1][8]. By disrupting these pathways, sorafenib deprives HCC cells of essential oxygen and nutrients, induces endothelial cell apoptosis, and limits tumor growth [3]. Additionally, sorafenib has been shown to modulate the tumor microenvironment (TME) by reducing extracellular matrix (ECM) stiffness and inhibiting transforming growth factor-beta (TGF-β)-mediated activation of cancer-associated fibroblasts (CAFs) [3].
3. Molecular Mechanism of Action
The development of sorafenib resistance in HCC is a highly complex, multifactorial process involving genetic, epigenetic, metabolic, and microenvironmental adaptations.
Epigenetic Regulation and Non-coding RNAs: Epigenetic modifications, including DNA methylation and RNA modifications, significantly alter gene expression to promote resistance. For instance, the MORC2-NF2/KIBRA axis causes DNA hypermethylation that inhibits Hippo signaling, enhancing tumor survival [1][3]. The m6A methyltransferase METTL3 stabilizes FOXO3 and lncRNA KIF9-AS1, driving resistance and cancer stemness [4][5]. Non-coding RNAs (ncRNAs) also play a pivotal role. MicroRNAs such as miR-21, miR-93, and miR-494 are upregulated in resistant cells, often hyperactivating the PTEN/AKT/mTOR pathway [2][5]. Conversely, tumor-suppressive miRNAs like miR-122 and miR-338-3p are frequently downregulated [2]. Long non-coding RNAs (lncRNAs) such as SNHG3, NEAT1, and circRNA-SORE act as molecular sponges or scaffolds to sustain oncogenic signaling and stabilize proteins like YBX1 [4][5].
Metabolic Reprogramming: Resistant HCC cells rewire their metabolism to survive the stress of kinase inhibition. Enhanced aerobic glycolysis is a hallmark of this resistance, driven by the upregulation of Hexokinase 2 (HK2), glucose transporters (GLUT1), and Pyruvate Kinase M2 (PKM2) [5][9]. Lipid and cholesterol metabolism are also altered; the overexpression of ATP citrate lyase (ACLY) and the SREBP2 pathway fuels de novo fatty acid synthesis and cholesterol homeostasis, providing energy and structural components for resistant cells [9].
Transport Processes and Exosomes: The upregulation of ATP-binding cassette (ABC) transporters, such as ABCB1 and ABCG2, actively effluxes sorafenib out of tumor cells, reducing its intracellular concentration [1][5]. Furthermore, exosomes mediate intercellular communication, transferring resistance-conferring molecules like miR-93, miR-1228-3p, and circUPF2 from resistant to sensitive cells, thereby propagating drug resistance throughout the tumor [1][5].
Regulated Cell Death (Ferroptosis and Autophagy): Sorafenib is unique among TKIs in its ability to induce ferroptosis, a form of iron-dependent lipid peroxidation [1]. However, HCC cells develop resistance by upregulating anti-ferroptotic factors like SLC7A11 (driven by YAP/TAZ) and Metallothionein-1G (MT-1G), or by altering iron metabolism via NCOA4 and TFR1 suppression [1][4][5]. Autophagy also plays a dual role; while sorafenib-induced autophagy can promote cell death, resistant cells often hijack autophagic pathways (e.g., via CD24 or AMPK activation) as a cytoprotective survival mechanism [1].
Tumor Microenvironment (TME) and Hypoxia: Sorafenib's anti-angiogenic effect paradoxically induces severe intratumoral hypoxia. This stabilizes Hypoxia-Inducible Factors (HIF-1α and HIF-2α), which activate compensatory survival pathways (e.g., TGF-α/EGFR) and metabolic shifts [1][3]. The TME also becomes highly immunosuppressive, characterized by the recruitment of tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and the upregulation of immune checkpoints like PD-1/PD-L1, which facilitate immune evasion [1][3].
Cancer Stem Cells (CSCs) and EMT: Sorafenib treatment can enrich the CSC population and trigger Epithelial-Mesenchymal Transition (EMT). Markers such as CD90, CD133, and OCT4 are upregulated, driven by pathways like Wnt/β-catenin and IL-6/STAT3, conferring a highly resistant, metastatic phenotype [1][3][5].
4. Structure-Activity Relationship (SAR)
While the traditional chemical structure-activity relationship of sorafenib highlights its ability to bind the ATP-binding pockets of multiple kinases (Raf, VEGFR, PDGFR), its physicochemical properties present significant clinical challenges. Sorafenib exhibits low aqueous solubility, rapid clearance from systemic circulation, and poor tumor-specific accumulation [3]. To modify its biological activity profile and overcome these structural limitations, researchers have engineered nanoparticle (NP) delivery systems (typically 5–200 nm in size) [7]. The surface chemistry and zeta potential of these nanocarriers dictate the formation of a "protein corona" in the blood, which influences biodistribution [3]. By encapsulating sorafenib in lipid-based, polymeric, or inorganic NPs, its solubility is enhanced, degradation is reduced, and the drug can bypass physiological barriers (such as the EPR effect) to achieve targeted delivery, thereby improving its therapeutic index and overcoming efflux pump-mediated resistance [3][7].
5. Current Limitations
The clinical utility of sorafenib is constrained by several major limitations. First, the overall response rate is low, and the majority of patients develop acquired resistance within six months of initiating therapy [1]. Second, sorafenib administration is associated with significant dose-limiting toxicities, including hand-foot skin reactions, hypertension, weight loss, and severe gastrointestinal issues (e.g., diarrhea), which frequently lead to treatment discontinuation [1][3]. Third, the profound intratumoral heterogeneity (ITH) of HCC means that not all tumor cells rely on the Raf/MEK/ERK or VEGFR pathways, allowing resistant clones to survive and repopulate the tumor [5][7]. Finally, the drug's inherent hydrophobicity and poor pharmacokinetic profile limit its bioavailability and penetration into the dense, fibrotic extracellular matrix of HCC tumors [3].
6. Future Perspectives
To overcome sorafenib resistance, future therapeutic strategies are shifting towards combination regimens and advanced delivery technologies. Combining sorafenib with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) shows great promise in reversing TME immunosuppression [1][3]. Additionally, co-administering sorafenib with inhibitors of compensatory pathways—such as the PI3K/mTOR inhibitor BEZ235 or HIF-2α inhibitors—can synergistically induce apoptosis in resistant cells [1][3].
Smart nanomedicine platforms, including stimuli-responsive nanoparticles that release drugs in response to the acidic or hypoxic TME, will be crucial for maximizing efficacy while minimizing systemic toxicity [3][7]. Furthermore, targeting metabolic vulnerabilities, such as inhibiting glycolysis (HK2) or lipid synthesis (ACLY), offers a novel angle to starve resistant cells [9]. Finally, the integration of precision medicine tools, such as dynamic surveillance via circulating tumor DNA (ctDNA) and drug screening using patient-derived xenografts (PDX) and organoids (PDOs), will enable clinicians to predict resistance early and tailor individualized treatment sequences for HCC patients [6].
